Maya Hites - Infectious Diseases

Author Information

Maya Hites is affiliated with the Department of Infectious Diseases at CUB-Erasme, Université Libre de Bruxelles in Brussels, Belgium. Her work primarily focuses on infectious diseases, with a significant emphasis on the treatment and management of infections, particularly in critically ill patients. Her research also delves into the dynamics of viral infections, such as COVID-19, and evaluates the efficacy of novel treatment regimens.

Research Contributions

Maya Hites has made substantial contributions to the field of infectious diseases, particularly in understanding and optimizing treatment regimens for critically ill patients. Her research includes a rapid review of novel antibiotic drug regimens, the modeling analysis of remdesivir's effect in COVID-19 patients, and the exploration of unproven "cures" like hydroxychloroquine and ivermectin. She has also contributed to studies on the efficacy of the COVID-19 vaccine SCB-2019 and the use of bacteriophage therapy combined with antibiotics for treating drug-resistant infections. Her work is crucial in shaping treatment protocols and advancing knowledge in infectious disease management.

Aliases

Maya Hites is also known by the aliases M Hites and M. Hites. These variations may appear in different publications or databases.

Publication and Citation Metrics

Metric	Value
Total Citation Count	1780
h-index	23
Total Paper Count	104

Publications:

Drug Regimens of Novel Antibiotics in Critically Ill Patients with Varying Renal Functions: A Rapid Review

DOI: 10.3390/antibiotics11050546

Year: 2022

Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.

DOI: 10.1093/jac/dkac048

Year: 2022

From hydroxychloroquine to ivermectin: how unproven “cures” can go viral

DOI: 10.1016/j.cmi.2022.01.008

Year: 2022

Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment.

DOI: 10.1080/17425255.2022.2056012

Year: 2022

Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial

DOI: 10.1101/2022.03.30.22273206

Year: 2022

Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae

DOI: 10.1038/s41467-021-27656-z

Year: 2022

Antimicrobial susceptibly testing determined by Alfred 60/AST (Alifax®) in a multi-sites' lab: performance's evaluation and optimisation of workflow.

DOI: 10.1016/j.mimet.2022.106433

Year: 2022

Accelerating clinical trial implementation in the context of the COVID-19 pandemic: author's response

DOI: 10.1016/j.cmi.2021.12.014

Year: 2022

Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial

DOI: 10.1016/S0140-6736(22)00055-1

Year: 2022

Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group

DOI: 10.1016/j.cmi.2021.10.011

Year: 2021

How Do Decongestants Work?

How to Combat Antimicrobial Resistance?

What Are the Benefits of Early Detection?

What are Emerging Viral Threats?

How Can Genomics Improve Diagnostics?

How Can Malaria Be Prevented?

What are the Benefits of Gene Therapy and Immunotherapy?

What is the Prognosis for Individuals with HSV?

What is the Prognosis for Infected Individuals?

What Are the Limitations of Blood Tests?

Partnered Content Networks

Relevant Topics